CTLA4 and cancer: BsAbs are a viable strategy to overcome this obstacle because the simultaneous co-blockade of two cancer antigens, such as CTLA-4 and PD-1, primarily in the TME by BsAbs may restrict immune responses, particularly to the tumor site.